Healthcare / BiotechnologyNasdaqGS
$3.98
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-75.8M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$866M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-17.5%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
+44.9%
FCF CAGR
—
FCF margin
-99.5%
FCF / Net income
4.36x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $76.2M · net income $-17.4M · FCF $-75.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | $76.2M | $76.2M | $138.1M | $101.2M | $53.2M | $37.3M | $68.4M | $26.9M | $59.5M | $71.6M | $12.8M | $7.7M | $5.1M | $888000.00 |
| Net Income | $-17.4M | $-17.4M | $31.9M | $-569000.00 | $-99.3M | $-115.9M | $-64.8M | $-132.8M | $-84.6M | $-43.1M | $-58.9M | $-35.4M | $-30.3M | $-15.1M |
| EBITDA | — | — | — | — | — | — | — | — | $-76.0M | $-44.6M | $-57.9M | $-32.0M | $-29.0M | $-14.3M |
| Operating Margin | -29.3% | -29.3% | 18.1% | -6.4% | -190.6% | -311.0% | -117.7% | -525.9% | -130.9% | -64.6% | -463.9% | -430.5% | -586.3% | -1684.2% |
| Net Margin | -22.8% | -22.8% | 23.1% | -0.6% | -186.8% | -310.5% | -94.7% | -493.7% | -142.2% | -60.2% | -458.5% | -458.7% | -597.0% | -1705.3% |
| Balance Sheet | ||||||||||||||
| Debt/Equity | — | — | — | — | — | — | — | — | — | — | — | — | -0.02 | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-75.8M | $-75.8M | $-86.5M | $-56.9M | $-112.5M | $-120.6M | $3.0M | $-144.0M | $-79.3M | $168.8M | $-4.2M | — | — | — |
| Returns | ||||||||||||||
| ROE | -17.5% | -17.5% | -6988.8% | 1.2% | 115.8% | 25244.0% | 833.8% | -521.5% | -62.3% | -61.7% | -75.1% | -28.1% | 38.6% | 34.2% |
| Growth & Yield | ||||||||||||||
| Revenue Growth | -44.8% | -44.8% | 36.4% | 90.4% | 42.5% | -45.5% | 154.4% | -54.8% | -16.9% | 457.6% | 66.6% | 51.9% | 471.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.